INDIANAPOLIS, August 19, 2026, 14:39 EDT — U.S. cash markets remained open.
- Eli Lilly shares ended August 18 only 1.9% shy of their all-time high.
- Volume climbed 60% in the second quarter, offsetting a 13% drop in realized prices.
- Mounjaro and Zepbound accounted for roughly 64% of revenue during the quarter.
Eli Lilly and Company NYSE:LLY finished Tuesday at $1,225.73, standing 1.9% under its highest level. The stock rose 3.6% as investors responded to the pharmaceutical firm’s ongoing earnings strength.
The rally’s fundamentals are clear. Revenue for the second quarter surged 48% to $22.97 billion. Sales volume increased 60%, though realized prices declined 13%. This combination forms the main test for investors.
| Q2 measure | 2026 | 2025 | Change |
|---|---|---|---|
| Revenue | $22.97 billion | $15.56 billion | up 48% |
| Reported net income | $7.10 billion | $5.66 billion | up 25% |
| Reported EPS | $7.94 | $6.29 | up 26% |
| Non-GAAP EPS | $8.38 | $6.31 | up 33% |
The stock gained 6.9% across August 5 and 6 following the report. As of Tuesday’s close, it stood 9.9% higher compared to its pre-earnings level on August 4. This surpassed the approximately 6% shift options traders had anticipated before the results.
Pressure on prices continues. U.S. revenue increased 33% as volume climbed 37%. Realized prices in the U.S. dropped 3%, or around 9% when rebate-estimate adjustments are excluded.
| Growth bridge | Worldwide | United States |
|---|---|---|
| Revenue increase | +48% | +33% |
| Contribution from volume | +60% | +37% |
| Impact from realized price | -13% | -3% |
| U.S. base price, not counting estimate updates | Not disclosed | Roughly -9% |
Mounjaro brought in $9.9 billion in revenue for the quarter, while Zepbound contributed $4.9 billion. Combined, these injectable drugs accounted for around 64% of the firm’s sales, highlighting both significant scale and risk from such concentration.
The upcoming competition centers on oral therapies. Novo Nordisk NYSE:NVO maintains roughly 90% share of the oral GLP-1 segment through Wegovy. While Lilly’s Foundayo is expanding at a quicker pace, its initial prescription numbers are still behind.
| Oral obesity measure | Lilly Foundayo | Novo oral Wegovy |
|---|---|---|
| Number of U.S. prescriptions in early August | 38,900 | 163,000 |
| Most recent reported weekly increase | +14% | Below Foundayo |
| Q2 revenue | $98 million | Roughly $500 million |
| Dosing requirement | No restrictions on eating or drinking | Take on empty stomach; wait 30 minutes |
Novo launched a fresh late-stage Wegovy trial on August 12, aiming to assess lower maintenance doses through 2028. The effort addresses both costs and side effects, factors that could further intensify pricing pressures in this segment.
Lilly increased its 2026 revenue outlook to a range of $85 billion to $87 billion. The company also pledged an additional $4.5 billion for manufacturing in Indiana. Chief Executive David Ricks stated that the business maintains its momentum and highlighted retatrutide along with expanded production capacity.
Optimism remains on Wall Street, though upside potential is limited. The consensus price objective of $1,277 stands just 4.2% higher than where shares finished on Tuesday. The projected trading band of $850 to $1,600 covers a 61 percentage point range at current values.
| Firm | Date | Recommendation | Price target | Upside vs. $1,225.73 |
|---|---|---|---|---|
| Cantor Fitzgerald | Aug. 6 | Overweight | $1,410 | 15.0% |
| Morgan Stanley | Aug. 6 | Overweight | $1,419 | 15.8% |
| BMO Capital | Aug. 6 | Outperform | $1,400 | 14.2% |
| Wells Fargo | Aug. 6 | Overweight | $1,330 | 8.5% |
| RBC Capital | July 8 | Outperform | $1,500 | 22.4% |
The immediate issue is not the presence of demand, but whether volume growth can continue to outpace falling prices. Foundayo brings an extra channel, though it accounts for under 1% of present quarterly sales.
Risks: Growth could be pressured by a slowdown in prescriptions, higher rebates, or possible safety issues. Production setbacks and intensified competition from Novo would further increase valuation demands.
Related articles: NYSE:LLY
Lilly's growth has a narrower valuation runway
The growth bridge
Obesity franchise concentration
Two-day earnings reaction
Wall Street's target spread
The investor read
Lilly is proving it can trade price for reach. Volume growth has more than offset lower realized prices. The burden now shifts to durability: prescriptions must keep rising, manufacturing must arrive on time, and Foundayo must close a large oral-market gap with Novo. At $1,225.73, the stock already discounts much of the near-term earnings beat.
